18/06/2026
How much are psoriasis and psoriatic arthritis really costing our health systems and economies?
Our new research, published in Dermatology and Therapy, found that cardiovascular disease, diabetes, obesity and depression, associated with psoriasis and psoriatic arthritis, generate substantial healthcare costs and productivity losses, amounting to billions over time.
The study estimates that these conditions generate:
🔸USD 5.2 billion every year and USD 153 billion over a lifetime in the United States
🔸EUR 55 million every year and EUR 1.4 billion over a lifetime in Denmark
🔸USD 22 million every year and USD 673 million over a lifetime in Vietnam
The good news? Earlier effective treatment could reduce this burden up to 48%.
How?
Reducing the risk of comorbidities means fewer hospitalizations, less medication costs, as well as improved mental health, increased productivity and better long-term health for over 100 million people living with psoriasis and psoriatic arthritis.
The message is clear: psoriasis and psoriatic arthritis are much more than skin and joint symptoms. They cost billions in healthcare and productivity losses and place a substantial burden on societies and economies.
A special thanks to Raquel Vaz, Scientific Project Lead at IFPA and co-author of the study, whose hard work helped bring this important evidence to light.
📖 Read the full article to explore the hidden cost of psoriatic disease and why earlier intervention matters. Link is in the first comment 👇